These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 22882843)

  • 1. Effect of high-dose rosuvastatin loading before percutaneous coronary intervention in female patients with non-ST-segment elevation acute coronary syndrome.
    Gao Y; Jia ZM; Sun YJ; Zhang ZH; Ren LN; Qi GX
    Chin Med J (Engl); 2012 Jul; 125(13):2250-4. PubMed ID: 22882843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of a single high loading dose of rosuvastatin on percutaneous coronary intervention for acute coronary syndromes.
    Wang Z; Dai H; Xing M; Yu Z; Lin X; Wang S; Zhang J; Hou F; Ma Y; Ren Y; Tan K; Wang Y; Ge Z
    J Cardiovasc Pharmacol Ther; 2013 Jul; 18(4):327-33. PubMed ID: 23364255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The beneficial effect of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome.
    Yun KH; Jeong MH; Oh SK; Rhee SJ; Park EM; Lee EM; Yoo NJ; Kim NH; Ahn YK; Jeong JW
    Int J Cardiol; 2009 Nov; 137(3):246-51. PubMed ID: 18706705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 12-month follow-up results of high dose rosuvastatin loading before percutaneous coronary intervention in patients with acute coronary syndrome.
    Yun KH; Oh SK; Rhee SJ; Yoo NJ; Kim NH; Jeong JW
    Int J Cardiol; 2011 Jan; 146(1):68-72. PubMed ID: 20471117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of high reloading ROsuvastatin and Atorvastatin pretreatment in patients undergoing elective PCI to reduce the incidence of MyocArdial periprocedural necrosis. The ROMA II trial.
    Sardella G; Lucisano L; Mancone M; Conti G; Calcagno S; Stio RE; Pennacchi M; Biondi-Zoccai G; Canali E; Fedele F
    Int J Cardiol; 2013 Oct; 168(4):3715-20. PubMed ID: 23849964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rosuvastatin pretreatment in patients undergoing elective PCI to reduce the incidence of myocardial periprocedural necrosis: the ROMA trial.
    Sardella G; Conti G; Donahue M; Mancone M; Canali E; De Carlo C; Di Roma A; Calcagno S; Lucisano L; Fedele F
    Catheter Cardiovasc Interv; 2013 Jan; 81(1):E36-43. PubMed ID: 22517610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rosuvastatin-induced high-density lipoprotein changes in patients who underwent percutaneous coronary intervention for non-ST-segment elevation acute coronary syndrome.
    Yun KH; Shin SN; Ko JS; Rhee SJ; Kim NH; Oh SK; Jeong JW
    J Cardiol; 2012 Nov; 60(5):383-8. PubMed ID: 22884684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of rosuvastatin therapy on troponin I release following percutaneous coronary intervention in nonemergency patients (from the TIP 3 study).
    Veselka J; Hájek P; Tomašov P; Tesař D; Brůhová H; Matějovič M; Branny M; Studenčan M; Zemánek D
    Am J Cardiol; 2014 Feb; 113(3):446-51. PubMed ID: 24304551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rosuvastatin may reduce the incidence of cardiovascular events in patients with acute coronary syndromes receiving percutaneous coronary intervention by suppressing miR-155/SHIP-1 signaling pathway.
    Xie W; Li P; Wang Z; Chen J; Lin Z; Liang X; Mo Y
    Cardiovasc Ther; 2014 Dec; 32(6):276-82. PubMed ID: 25319951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of early intensive rosuvastatin therapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention (ROSEMARY Study).
    Ko YG; Won H; Shin DH; Kim JS; Kim BK; Choi D; Hong MK; Bae JH; Lee S; Lim DS; Jang Y
    Am J Cardiol; 2014 Jul; 114(1):29-35. PubMed ID: 24831577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Loading-Dose Rosuvastatin Therapy in Elderly Patients with Acute Coronary Syndromes Undergoing Elective Percutaneous Coronary Intervention.
    Jiao Y; Hu F; Zhang Z; Gong K; Sun X; Li A; Liu N
    Clin Drug Investig; 2015 Dec; 35(12):777-84. PubMed ID: 26387028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Rosuvastatin improves myocardial function and arteriosclerosis plaque in patients with ST-segment elevation after acute myocardial infarction and percutaneous coronary intervention].
    Lin ZP; Shu PC; Liao ZJ; Wang XQ; Liu Q
    Nan Fang Yi Ke Da Xue Xue Bao; 2011 Oct; 31(10):1789-91. PubMed ID: 22027793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early high-dose rosuvastatin and cardioprotection in the protective effect of rosuvastatin and antiplatelet therapy on contrast-induced acute kidney injury and myocardial damage in patients with acute coronary syndrome (PRATO-ACS) study.
    Leoncini M; Toso A; Maioli M; Tropeano F; Badia T; Villani S; Bellandi F
    Am Heart J; 2014 Nov; 168(5):792-7. PubMed ID: 25440809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects and mechanisms of high loading dose rosuvastatin therapy before percutaneous coronary intervention in patients with acute coronary syndrome.
    Luo J; Li J; Shen X; Hu X; Fang Z; Lv X; Zhou S
    Int J Cardiol; 2013 Sep; 167(5):2350-3. PubMed ID: 23194788
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy of high-dose clopidogrel treatment (600 mg) less than two hours before percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes.
    Feldman DN; Fakorede F; Minutello RM; Bergman G; Moussa I; Wong SC
    Am J Cardiol; 2010 Feb; 105(3):323-32. PubMed ID: 20102943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-oxidative stress effect of loading-dose rosuvastatin prior to percutaneous coronary intervention in patients with acute coronary syndrome: a prospective randomized controlled clinical trial.
    Liang D; Zhang Q; Yang H; Zhang R; Yan W; Gao H; Wang J; Zhang X; Chen Y; Cao F
    Clin Drug Investig; 2014 Nov; 34(11):773-81. PubMed ID: 25186834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statin loading before percutaneous coronary intervention: proposed mechanisms and applications.
    Nusca A; Melfi R; Patti G; Sciascio GD
    Future Cardiol; 2010 Sep; 6(5):579-89. PubMed ID: 20932108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel approaches for preventing or limiting events (Naples) II trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction.
    Briguori C; Visconti G; Focaccio A; Golia B; Chieffo A; Castelli A; Mussardo M; Montorfano M; Ricciardelli B; Colombo A
    J Am Coll Cardiol; 2009 Dec; 54(23):2157-63. PubMed ID: 19664895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between inflammation and benefits of early high-dose rosuvastatin on contrast-induced nephropathy in patients with acute coronary syndrome: the pathophysiological link in the PRATO-ACS study (Protective Effect of Rosuvastatin and Antiplatelet Therapy on Contrast-Induced Nephropathy and Myocardial Damage in Patients With Acute Coronary Syndrome Undergoing Coronary Intervention).
    Toso A; Leoncini M; Maioli M; Tropeano F; Di Vincenzo E; Villani S; Bellandi F
    JACC Cardiovasc Interv; 2014 Dec; 7(12):1421-9. PubMed ID: 25523533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of high-dose statin administered prior to coronary angioplasty on the incidence of cardiac events in patients with acute coronary syndrome.
    Chyrchel M; Rakowski T; Rzeszutko L; Legutko J; Dziewierz A; Dubiel JS; Dudek D
    Kardiol Pol; 2006 Dec; 64(12):1357-62; discussion 1363. PubMed ID: 17206539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.